Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: JOHN W. who wrote (3129)	12/4/1997 11:21:00 AM
From: Oliver & Co	Respond to of 6136

About 6-8 months ago, an inside source told me personally, that they were very happy with Japan-Tobacco, because it did not get into their business. However, Roche was another story. At times it seemed like Roche wanted to run the company. And that, they surely did not like. I am not at all surprised about seing Roche go. And as a businessman, if I can afford to run my business, and take new drugs to market, why am I going to let someone tell me what to do, and take a bite off my profits? With regards to the inside trading, if you look back, at least to October 1st, you will find several instances where big transactions in the options markets were taking place ahead of news. And David Crossen has been downgrading the stock on wrong,misguided information. And giving out at least misleading info. He should know very well that Glaxo and Vertex have the same drug. JLL